Tag: Xphyto
-
![Bionxt Solutions (BNXT.C) shows how pivots don’t have to mean resets]()
Bionxt Solutions (BNXT.C) shows how pivots don’t have to mean resets
Several years back, Hugh Rogers was in my office talking about his cannabis company. Way back then, the plan was to grow in Germany and be first on the continent, using an old wartime bunker as a ‘safe growing facility’. Those plans morphed quickly as the reality of the cannabis space became clear. The cannabis…
-
![XPhyto Therapeutics (XPHY.C) Signs Acquisition Agreement with 3a-Diagnostics, Enters Biosensor Market]()
XPhyto Therapeutics (XPHY.C) Signs Acquisition Agreement with 3a-Diagnostics, Enters Biosensor Market
XPhyto Therapeutics (XPHY.C) announced today that it has signed a definitive agreement for the acquisition of 3a-Diagnostics GmhB, Frickenhausen, Germany, XPhyto’s exclusive diagnostic development partner. “We have collaborated closely with the 3a-diagnostics team on several diagnostics products and have found them to be a highly innovative and focused partner. The successful development and recent launch…
-
Xphyto (XPHY.C) bulks up executive team as Covid-19 ravages Europe
The PCR test system demonstrated clinical accuracy in detecting SARS-CoV-2 RNA within 25 minutes, making it an ideal screening tool for international airports.
-
That was quick! Xphyto (XPHY.C) orders 9,600 Covid-19 PCR tests – stock up 67% year-to-date
“PCR tests are used to directly detect the presence of an antigen, rather than the presence of the body’s immune response, or antibodies,” states Medical Device Network, “By detecting viral RNA, which will be present in the body before symptoms of the disease are present,” the tests give a powerful early warning system.
-
![Xphyto (XPHY.C) assembles biotech/biz dream-team to launch 25-minute Covid-19 test]()
Xphyto (XPHY.C) assembles biotech/biz dream-team to launch 25-minute Covid-19 test
The PCR test system demonstrated clinical accuracy in detecting SARS-CoV-2 RNA within 25 minutes, making it an ideal screening tool for international airports.
-
![Xphyto’s (XPHY.C) lays out its ambitious Parkinson’s/Epilepsy/Depression/Multiple Sclerosis drug formulation strategy which includes heavy investment in psychedelic medicine]()
Xphyto’s (XPHY.C) lays out its ambitious Parkinson’s/Epilepsy/Depression/Multiple Sclerosis drug formulation strategy which includes heavy investment in psychedelic medicine
Xphyto describes itself as “a bioscience accelerator” “targeting growth through commercialization of its product pipeline”.
-
![Xphyto Therapeutics (XPHY.C) lays out their milestones and strategic guard-rails for 2021]()
Xphyto Therapeutics (XPHY.C) lays out their milestones and strategic guard-rails for 2021
In lieu of the American markets not opening today courtesy of the civic holiday, Xphyto Therapeutics (XPHY.C) has elected to provide a glimpse into their business strategy and milestones for 2021. As an overview, the company sees itself on the edge of a transformational change as their product development programs go from the laboratory to…
-
![Biotech Blitz: Xphyto (XPHY.C), Theralase (TLT.V), Caladrius (CLBS.Q), Volition Rx (VNRX.NYSE), Kane Biotech (KNE.V) and Bionexus (BGLC.OTC) stand & deliver]()
Biotech Blitz: Xphyto (XPHY.C), Theralase (TLT.V), Caladrius (CLBS.Q), Volition Rx (VNRX.NYSE), Kane Biotech (KNE.V) and Bionexus (BGLC.OTC) stand & deliver
On Thursday, December 17th, 2020 the Virtual Life Sciences Investor Forum (VLSIF) presents a six biotech companies.
-
![Xphyto (XPHY.C) targets industrial manufacture of psilocybin as U.S. voters weigh in on mushrooms]()
Xphyto (XPHY.C) targets industrial manufacture of psilocybin as U.S. voters weigh in on mushrooms
Today’s federal election results could change the regulatory landscape in Oregon and Washington DC, as the residents of those states will vote to decide if psilocybin should be decriminalised.
-
![Xphyto (XPHY.C) advances its Oral Dissolvable Film (ODF) technology for CBD and THC medical markets]()
Xphyto (XPHY.C) advances its Oral Dissolvable Film (ODF) technology for CBD and THC medical markets
Increased product efficacy and patient convenience is anticipated through faster onset of drug action, more predictable therapeutic activity and ease of use.
